NovaBridge Biosciences Sets March 9 Call to Review Phase 2a VIS-101 Data in Wet AMD

NovaBridge Biosciences ( (NBP) ) has issued an update.

NovaBridge Biosciences, a Nasdaq-listed global biotechnology platform company, develops oncology and ophthalmology assets including givastomig, a Claudin 18.2 x 4-1BB bispecific antibody in Phase 2 for gastric and other gastrointestinal cancers, and VIS-101, a dual VEGF-A/ANG-2 inhibitor for wet age-related macular degeneration (AMD), diabetic macular edema and retinal vein occlusion. The company also advances ragistomig for solid tumors in partnership with ABL Bio and holds ex-China rights to the anti-CD73 antibody uliledlimab, while maintaining majority ownership of ophthalmology specialist Visara, which manages VIS-101 rights outside Greater China and parts of Asia.

On March 3, 2026, NovaBridge announced it would host a virtual business update call on March 9, 2026, to review Phase 2a clinical data for VIS-101 in patients with wet AMD, underscoring the strategic importance of this ophthalmic candidate in its pipeline. The event, featuring senior leaders from NovaBridge, Visara and external retinal experts, signals that key mid-stage data could influence the company’s positioning in the competitive retinal disease market and inform expectations around the potential of VIS-101 as a more durable alternative to current standard-of-care therapies.

The most recent analyst rating on (NBP) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on NovaBridge Biosciences stock, see the NBP Stock Forecast page.

Spark’s Take on NBP Stock

According to Spark, TipRanks’ AI Analyst, NBP is a Neutral.

The score is primarily held back by deteriorated financial performance (no 2024 revenue, persistent losses, and ongoing cash burn) despite low leverage. Technicals are mildly bearish with price below key moving averages and a slightly negative MACD, while valuation is largely neutral because negative earnings make the P/E less informative and no dividend support is shown.

To see Spark’s full report on NBP stock, click here.

More about NovaBridge Biosciences

NovaBridge Biosciences is a global biotechnology platform company focused on accelerating access to innovative medicines by combining business development expertise with translational clinical development. Its pipeline is led by givastomig, a Claudin 18.2 x 4-1BB bispecific antibody in Phase 2 trials for Claudin 18.2-positive gastric and other gastrointestinal cancers, alongside VIS-101, a bifunctional biologic targeting VEGF-A and ANG-2 for retinal diseases.

The company also collaborates with ABL Bio on ragistomig, a PD-L1/4-1BB bispecific for solid tumors, and owns rights outside China to uliledlimab, an anti-CD73 antibody aimed at countering adenosine-driven immunosuppression in cancer. NovaBridge is the majority shareholder of Visara, a clinical-stage ophthalmic-focused biopharmaceutical firm that controls VIS-101 rights outside Greater China and certain Asian territories.

Average Trading Volume: 665,225

Technical Sentiment Signal: Hold

Current Market Cap: $397.8M

Find detailed analytics on NBP stock on TipRanks’ Stock Analysis page.